maridebart cafraglutide (MariTide)
(Redirected from Maridebart cafraglutide)
Indications
- investigational treatment of obesity
Dosage
- once monthly
- 140, 280, or 420 mg subcutaneous every 4 weeks
Mechanism of action
More general terms
References
- ↑ 1.0 1.1 Jastreboff AM, Ryan DH, Bays HE et al for the MariTide Phase 2 Obesity Trial Investigators. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025 Sep 4;393(9):843-857. PMID: https://pubmed.ncbi.nlm.nih.gov/40549887 Clinical Trial. https://www.nejm.org/doi/10.1056/NEJMoa2504214